Gestodene

CAS No. 60282-87-3

Gestodene( Gestodene | Gestodenum | Gestodeno | Gestoden | Gestodene )

Catalog No. M15249 CAS No. 60282-87-3

Gestodene(SHB 331;WL 70) is a progestogen hormonal contraceptive.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
1 mL x 10 mM in DMSO 48 In Stock
10MG 29 In Stock
25MG 40 In Stock
50MG 54 In Stock
100MG 79 In Stock
200MG 114 In Stock
500MG Get Quote In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Gestodene
  • Note
    Research use only, not for human use.
  • Brief Description
    Gestodene(SHB 331;WL 70) is a progestogen hormonal contraceptive.
  • Description
    Gestodene(SHB 331;WL 70) is a progestogen hormonal contraceptive.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    Gestodene | Gestodenum | Gestodeno | Gestoden | Gestodene
  • Pathway
    Endocrinology/Hormones
  • Target
    Estrogen Receptor/ERR
  • Recptor
    ER
  • Research Area
    Endocrinology
  • Indication
    ——

Chemical Information

  • CAS Number
    60282-87-3
  • Formula Weight
    310.43
  • Molecular Formula
    C21H26O2
  • Purity
    >98% (HPLC)
  • Solubility
    Ethanol: 8 mg/mL (25.77 mM); DMSO: 62 mg/mL (199.72 mM)
  • SMILES
    C#C[C@@]1(O)C=C[C@@]2([H])[C@]3([H])CC=C4CC(CC[C@]4([H])[C@@]3([H])CC[C@]12CC)=O
  • Chemical Name
    (17α)-13-Ethyl-17-hydroxy-18,19-dinorpregna-5,15-dien-20-yn-3-one

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1.Lidegaard ?, et al. BMJ. 2011 Oct 25;343:d6423.
molnova catalog
related products
  • AZD9496

    A potent, selective estrogen receptor downregulator (SERD) with ER downregulation pIC50 of 9.68.

  • OP-1074

    OP-1074 (OP1074) is a potent, selective ER degrader (SERD), shows specific antiestrogenic activity for both ERα and Erβ.

  • Fulvestrant

    Fulvestrant is a drug treatment of hormone receptor-positive metastatic breast Y in post-menopausal women with disease progression following anti-estrogen therapy.